$104.68
0.310.3%
Last update: Oct 2, 4:00 PM
$104.68
0.310.3%
Haemonetics Corp
HAENYSE
Haemonetics (HAE) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
Haemonetics (HAE) last issued guidance on August 6, 2026 for fiscal year 2027. The company guided revenue in the range of $1.4B - $1.44B for the period.
Compared to prior guidance, Haemonetics maintained its revenue forecast from a prior range of $1.41B - $1.43B.
Haemonetics has issued 17 guidance updates between November 7, 2022 and August 6, 2026. During this period, the company raised its outlook 9 times and lowered it 1 time, providing investors with insight into management's evolving expectations.
| Metric | Q1 '27 | Q4 '26 | Q3 '26 | Q2 '26 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $1.09 | $1.27 | $1.26 | $1.11 |
| Actual | $1.14 | $1.29 | $1.31 | $1.27 |
| Surprise | +4.59% | +1.57% | +3.97% | +14.4% |
| Revenue | ||||
| Estimate | $329.2M | $337.1M | $333.3M | $311.3M |
| Actual | $339.4M | $346.4M | $339.0M | $327.3M |
| Surprise | +3.10% | +2.74% | +1.70% | +5.14% |
| Metric | Q2 '27E | Q3 '27E | Q4 '27E | Q1 '28E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $1.29 | $1.36 | $1.48 | $1.26 |
| Revenue | ||||
| Consensus | $345.5M | $357.6M | — | — |
| Fiscal Quarter | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Q1 | Aug 6, 2026 | $1.14 | $1.09 | 4.59 % |
| Q4 | May 7, 2026 | $1.29 | $1.27 | 1.57 % |
| Q3 | Feb 5, 2026 | $1.31 | $1.26 | 3.97 % |
| Q2 | Nov 6, 2025 | $1.27 | $1.11 | 14.4 % |
| Fiscal Quarter | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
|---|---|---|---|---|
| Q1 | Aug 6, 2026 | $339.38M | $329.19M | 3.10 % |
| Q4 | May 7, 2026 | $346.35M | $337.12M | 2.74 % |
| Q3 | Feb 5, 2026 | $338.97M | $333.30M | 1.70 % |
| Q2 | Nov 6, 2025 | $327.32M | $311.32M | 5.14 % |
